Analystreport

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $85.00 to $82.00. They now have an "equal weight" rating

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com